Adding cetuximab to vemurafenib in xenografts experiments resulted in increased antitumor activity and improved survival[124] and combined administration of BRAF and EGFR inhibitors induces tumor regression in most patients[116,125-127]. This evidence concerns the gene BRAF and neoplasm.